Trials / Completed
CompletedNCT02945228
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 449 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.
Conditions
Timeline
- Start date
- 2016-10-26
- Primary completion
- 2019-07-26
- Completion
- 2019-07-26
- First posted
- 2016-10-26
- Last updated
- 2020-06-12
Locations
170 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02945228. Inclusion in this directory is not an endorsement.